Skip to content
Washington Rheumatology Alliance

Washington Rheumatology Alliance

Menu

  • Home
  • About
    • A Message from our President
    • Mission Statement
    • Officers
    • Membership Application/Annual Dues Form
    • Industry Acknowledgements
  • Initiatives
    • WRA Rheumatologists’ Compensation Survey
    • Rheumatology Care Alliance Learning Collaborative
    • Rheumatology Medical Home Demonstration Project
    • Quality Improvement Measurement
  • Action Center
    • Advocacy
    • News and Updates
  • Events
    • Annual Conference
      • 2023 Exhibitor Interest Form
      • 16th Annual Conference Registration
    • Hotel Information
    • Travel & Transportation
  • Resources
    • Online Resources
    • Opportunities
  • Contact Us

News

2023 WRA Annual Meeting Agenda

Linda Krause August 28, 2023 News Read more

CSRO Action Alert

Earlier this year, Congressman Ami Bera, MD (D-CA-07) and Congressman Larry Bucshon, MD (R-IN-08) introduced legislation to provide relief for the large Medicare Physician Fee Schedule reimbursement cuts that are currently set to take effect on January 1, 2023. This legislation, Supporting Medicare Providers

Jena Rehm November 29, 2022November 29, 2022 Home Page, News Read more

Office of Inspector General: MAOs & Pre Authorization Requests

April 2022: Some Medicare Advantage Organization Denials of Prior Authorization Requests Raise Concerns About Beneficiary Access to Medically Necessary Care With there being the potential concern of MAOs having the ability to increase profits by denying payments and access to

Jena Rehm May 3, 2022May 3, 2022 Home Page, News Read more

Introducing Our Stories Rx

As an initial convening, Our Stories Rx is hosting a virtual roundtable conversation with Antonio Ciaccia, who served as the government affairs director for the Ohio Pharmacists Association in 2018, when a state audit revealed a PBM-led spread pricing scheme

Washington Rheumatology Alliance June 23, 2021June 23, 2021 Home Page, News Read more

Genentech Stance on Most Favored Nations (MFN) Model

On December 15, 2020, Genentech led a discussion about how the Most Favored Nations (MFN) model threatens provider and patient access to existing and future medicines; we share your concerns that this could have a detrimental impact on your practice

Washington Rheumatology Alliance January 11, 2021January 11, 2021 Home Page, News Read more

Downloadable Resources from the Arthritis Foundation

The Arthritis Foundation has free downloadable brochures and fact sheets through the AF Store​ that you can save to your office desktop. The brochures and fact sheets can be e-mailed to patients or you can print copies in-office and hand

Washington Rheumatology Alliance November 6, 2020 Home Page, News Read more

Biosimilars Could Generate $100 Billion in Savings Over Next Five Years, New Report Finds

WASHINGTON, D.C. — A new report from the IQVIA Institute for Human Data Science has determined that biosimilars are on track to reduce drug costs by $100 billion over the next five years if their use rises. The future of this lower-cost

Washington Rheumatology Alliance October 13, 2020 Home Page, News Read more

Coronavirus: What Chronic Illness Patients Need to Know

From CreakyJoints: We’ve been hearing many questions and concerns from our global patient community about the continued spread of coronavirus across the U.S. and around the world. And while people with disabilities and chronic diseases have even more of a

Washington Rheumatology Alliance August 24, 2020August 24, 2020 Home Page, News Read more

Regence Rituxan to Ruxience has been Reversed

Regence Policy Reversed: The decision from Regence to mandate the switch from Rituxan patients to Ruxience has been reversed and Regence will approve Rituxan patients currently on treatment to continue for 1 year. If you have already submitted the authorization

Washington Rheumatology Alliance July 21, 2020July 21, 2020 Home Page, News Read more

Interstitial lung disease exacerbates rheumatoid arthritis activity, related conditions

Patients with interstitial lung disease demonstrated a higher proportion of comorbidities and rheumatoid arthritis activity, as well as rheumatoid arthritis-related conditions, according to a presenter at the EULAR 2020 Virtual Congress. “Interstitial lung disease is a common extra-articular manifestation of

Washington Rheumatology Alliance June 9, 2020 Home Page, News Read more
  • « Previous

Search the WRA

WRA Learning Collaborative

Find out about the new WRA Learning Collaborative.

docs

WRA Newsroom

  • 2023 WRA Annual Meeting Agenda
  • Thank you for Attending the 2023 WRA Annual Meeting!
  • TAKE ACTION: Sign in ‘PRO’ to Share the Savings!
  • CSRO Action Alert
  • Join us for the Arthritis Foundation Bone Bash

Washington Rheumatology Alliance

2001 6th Ave, Suite 2700
Seattle, WA 98121
206-956-3621
Jena Rehm, Executive Director

Copyright © 2023 Washington Rheumatology Alliance. All rights reserved. Theme Spacious by ThemeGrill. Powered by: WordPress.